(11) 98705-3426
TrademarkIQ íconeTrademarkIQ
Voltar para busca
Dado oficial do USPTO

VIVAGEL

Sabia que essa marca já está registrada no Estados Unidos?

Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.

Active USPTO registrationTipo: VerbalEscritório: US

Snapshot rápido

VIVAGEL

ST13

US500000079197477

Classe

5, 10

Pedido

79197477

Registro

5477567

Diagnóstico de risco e oportunidade

Leitura executiva para decisão de naming, protocolo e monitoramento.

Atenção: há risco ativo

Situação USPTO

Active USPTO registration

Tipo de processo

Pedido e registro

Eventos registrados

58

Atualização mais recente

10/04/2026

Classificação

Registrada

Tipo de marca

Verbal

Classes Nice

5, 10

Data de depósito

02/05/2016

Data de registro

29/05/2018

Data de expiração

-

Ação recomendada

Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.

Próximo passo

Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.

Dados completos do processo

Campos estruturados da autoridade responsável e do histórico oficial.

Data da situação

13/12/2024

Última transação

10/04/2026

Escritório responsável

United States Patent and Trademark Office

Código da situação

709

Cadastro oficial

Principal Register

Código do desenho

4

Tipo de titular

82

Localização do titular

AU

Examinador

ALLEN, BIANCA LEIGH

Unidade examinadora

N50

Localização atual

TMO LAW OFFICE 123

Titulares e representantes

Titulares

Starpharma Pty Ltd
Starpharma Pty Limited

Representantes

Starpharma Pty Limited

Classificação técnica

Classes Nice

Classe 5Classe 10

Códigos Vienna

Sem códigos Vienna disponíveis.

Produtos e serviços

Classe 5

Pharmaceuticals, pharmaceutical preparations, and pharmaceutical drugs for medical purposes for prevention of viral and bacterial disease, namely, bacterial vaginosis, herpes simplex virus, human papilloma virus, and human immunodeficiency virus (HIV); chemical preparations for pharmaceutical and medical purposes for the prevention of bacterial vaginosis, herpes simplex virus, human papilloma virus and human immunodeficiency virus (HIV); chemical compounds in the nature of antimicrobial or ph balancing or microbial balancing substances all for medical purposes, namely, for treating and preventing vaginal microbial imbalance, vaginal pH imbalance, vaginal odor and discharge, bacterial vaginosis, viral STD, vaginaitis, vaginal thrush, vaginal disease symptom relief including itching, odor, and discharge, for maintaining a healthy balance of vaginal flora and for the reestablishment of the bacterial vaginal flora; polyvalent compounds and dendrimers sold as integral component parts of pharmaceuticals preparations all for medical purposes for the treatment and prevention of bacterial vaginosis, herpes simplex virus, human papilloma virus, human immunodeficiency virus (HIV); antimicrobial preparations, namely, microbicidal preparations in the nature of gels, films, solutions, lubricants for vaginal and rectal use for prevention of bacterial vaginosis, herpes simplex virus, human papilloma virus, human immunodeficiency virus (HIV); chemical contraceptives, namely, sponges, gels, foams, creams, films, solutions, suspensions and lotions for use in preventing HIV and other sexually transmitted infections; prophylactic preparations for prevention of pregnancy and microbial disease of the reproductive system, namely, chemical contraceptives and antibacterial preparations in the nature of sponges, suppositories, sexual lubricants, gels, foams, creams, films, solutions, suspensions and lotions; pharmaceutical preparations in the nature of vaginal gels and lubricants all for the prevention of pregnancy and sexually transmitted infections and diseases of the human reproductive system

Classe 10

Contraceptive apparatus, namely, intravaginal cervical barriers; prophylactic instruments for use to prevent pregnancy and disease, namely, condoms, diaphragms, and intrauterine devices

Publicações

Histórico de despachos e eventos da marca no USPTO.

58 publicações encontradas

RNWL

INTERNATIONAL REGISTRATION RENEWED

09/04/2026

Further Decision Processed by IB

19/03/2026

XXSS

GENERIC MADRID TRANSACTION SENT TO IB

04/02/2026

INNA

INVALIDATION REVIEWED - NO ACTION REQUIRED BY OFFICE

04/02/2026

XXCR

GENERIC MADRID TRANSACTION CREATED

04/02/2026

INTR

TOTAL INVALIDATION OF REG EXT PROTECTION CREATED

13/08/2025

C71T

CANCELLED SECTION 71

13/12/2024

REM3

COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED

29/05/2023

ADCH

CHANGE OF NAME/ADDRESS REC'D FROM IB

07/06/2019

NREP

NEW REPRESENTATIVE AT IB RECEIVED

26/04/2019

COC.

CORRECTION UNDER SECTION 7 - PROCESSED

08/12/2018

CORR

CORRECTION FROM IB ENTERED - NO REVIEW REQUIRED

04/12/2018

APRE

CASE ASSIGNED TO POST REGISTRATION PARALEGAL

28/11/2018

TCCA

TEAS CHANGE OF CORRESPONDENCE RECEIVED

30/10/2018

ES7R

TEAS SECTION 7 REQUEST RECEIVED

30/10/2018

FINO

FINAL DECISION TRANSACTION PROCESSED BY IB

06/10/2018

FICS

FINAL DISPOSITION NOTICE SENT TO IB

13/09/2018

FIMP

FINAL DISPOSITION PROCESSED

13/09/2018

FICR

FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB

29/08/2018

R.PR

REGISTERED-PRINCIPAL REGISTER

29/05/2018

GPNX

NOTIFICATION PROCESSED BY IB

16/03/2018

PUBO

PUBLISHED FOR OPPOSITION

13/03/2018

OPNS

NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB

21/02/2018

OP2R

NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB

21/02/2018

NPUB

NOTICE OF PUBLICATION

21/02/2018

EXPT

EXPARTE APPEAL TERMINATED

06/02/2018

CNSA

APPROVED FOR PUB - PRINCIPAL REGISTER

06/02/2018

CNEA

EXAMINERS AMENDMENT MAILED

06/02/2018

XAEC

EXAMINER'S AMENDMENT ENTERED

06/02/2018

CNEA

EXAMINERS AMENDMENT -WRITTEN

06/02/2018

TEME

TEAS/EMAIL CORRESPONDENCE ENTERED

23/01/2018

CRFA

CORRESPONDENCE RECEIVED IN LAW OFFICE

23/01/2018

EXPI

EX PARTE APPEAL-INSTITUTED

22/01/2018

JURT

JURISDICTION RESTORED TO EXAMINING ATTORNEY

22/01/2018

EXAF

EXPARTE APPEAL RECEIVED AT TTAB

22/01/2018

ERFR

TEAS REQUEST FOR RECONSIDERATION RECEIVED

21/01/2018

NREP

NEW REPRESENTATIVE AT IB RECEIVED

27/07/2017

CNFR

FINAL REFUSAL MAILED

21/07/2017

CNFR

FINAL REFUSAL WRITTEN

20/07/2017

INNP

PARTIAL INVALIDATION PROCESSED BY THE IB

07/07/2017

TEME

TEAS/EMAIL CORRESPONDENCE ENTERED

27/06/2017

CRFA

CORRESPONDENCE RECEIVED IN LAW OFFICE

27/06/2017

ALIE

ASSIGNED TO LIE

23/06/2017

RFNT

REFUSAL PROCESSED BY IB

09/06/2017

TROA

TEAS RESPONSE TO OFFICE ACTION RECEIVED

25/05/2017

NREP

NEW REPRESENTATIVE AT IB RECEIVED

18/05/2017

CRCV

CORRECTION TRANSACTION RECEIVED FROM IB

28/04/2017

NREP

NEW REPRESENTATIVE AT IB RECEIVED

10/02/2017

RFCS

NON-FINAL ACTION MAILED - REFUSAL SENT TO IB

09/02/2017

RFRR

REFUSAL PROCESSED BY MPU

09/02/2017

RFCR

NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW

09/02/2017

CNRT

NON-FINAL ACTION WRITTEN

08/02/2017

DOCK

ASSIGNED TO EXAMINER

06/02/2017

MAFR

APPLICATION FILING RECEIPT MAILED

20/12/2016

NREP

NEW REPRESENTATIVE AT IB RECEIVED

16/12/2016

NWOS

NEW APPLICATION OFFICE SUPPLIED DATA ENTERED

15/12/2016

LIMI

LIMITATION FROM ORIGINAL APPLICATION ENTERED

12/12/2016

SDRC

SN ASSIGNED FOR SECT 66A SUBSEQ DESIG FROM IB

01/12/2016

Proteção contínua da sua marca

Seja avisado a cada novo depósito que ameace VIVAGEL ou a sua marca.

Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.